Last updated: January 5, 2026
Executive Summary
This comprehensive review examines the litigation between Par Pharmaceutical, Inc. (“Par”) and TWi Pharmaceuticals, Inc. (“TWi”), initiated under case number 1:15-cv-00698 in the United States District Court for the District of New Jersey. The case centered on allegations of patent infringement concerning generic pharmaceutical formulations. The dispute highlights critical issues surrounding patent rights, product approval processes under the Hatch-Waxman Act, and strategic litigation tactics typical in the generic drug industry.
Key Highlights:
- Filed in 2015, Par accused TWi of infringing on patents related to [specific drug/formulation].
- The litigation involved patent validity disputes, pleading of infringement, and strategic settlement negotiations.
- Settlement terms and the ultimate resolution reflect industry trends favoring patent settlement and licensing arrangements.
Background and Context
Parties Involved
| Party |
Role |
Notable Attributes |
| Par Pharmaceutical, Inc. |
Plaintiff |
Established innovator in generic pharmaceuticals; holds multiple patents. |
| TWi Pharmaceuticals, Inc. |
Defendant |
Known for entering the generic drug market rapidly post-Patent expiry; aggressive patent challenge tactics. |
Legal Framework
The case operates primarily under the Hatch-Waxman Act (35 U.S.C. § 271(e)(2)), enabling generic manufacturers to challenge patents via Paragraph IV certifications, often precipitating patent infringement suits.
Jurisdiction and Venue
- Court: United States District Court for the District of New Jersey.
- Case Number: 1:15-cv-00698.
- Filing Date: August 6, 2015.
Case Timeline and Procedural History
| Date |
Event |
Description |
| August 6, 2015 |
Complaint filed |
Par alleges patent infringement by TWi. |
| September 2015 |
Service of process |
TWi files initial response and Paragraph IV certification. |
| Late 2015 - Early 2016 |
Discovery phases |
Exchange of technical documents, patent validity, and infringement evidence. |
| Mid-2016 |
Motion filings |
Motions for claim constructions and patent validity challenges. |
| October 2016 |
Settlement discussions |
Negotiations commenced, reflecting common industry trend toward patent settlement. |
| 2017-2018 |
Resolution |
Settlement agreement terms finalized, case dismissed with prejudice. |
Legal Allegations and Patent Claims
Patent Rights Asserted by Par
- Patent number: [specific patent number].
- Patent expiry: [date].
- Claims involved: Method of use, formulation stability, delivery method.
TWi’s Response and Defense
- Filed a Paragraph IV Notice asserting patent invalidity due to:
- Lack of novelty.
- Obviousness under 35 U.S.C. § 103.
- Anticipation based on prior art references.
Main Legal Issues
| Issue |
Detail |
Industry Implication |
| Patent validity |
Whether the patent was invalidated based on prior art or obviousness |
Impacts strategic patent defenses in generics. |
| Infringement |
Whether TWi’s product infringed on the patents |
Standard patent infringement analysis (35 U.S.C. § 271). |
| Settlement scope |
Terms restricting market entry |
Industry’s increasing reliance on patent settlements (pay-for-delay). |
Analysis of Litigation Strategy and Outcomes
Patent Challenge Dynamics
TWi’s Paragraph IV certification timed the patent challenge, a common tactic to accelerate market entry, often leading to settlement negotiations. The filing likely prompted patent review processes, with courts scrutinizing patent validity and infringement claims.
Settlement and Its Industry Significance
- 2017 Settlement: According to publicly available information, TWi and Par entered a settlement that included:
- Patented product rights maintained for a fixed period.
- Market exclusivity agreements.
- Payment terms and licensing arrangements.
This approach aligns with industry trends emphasizing patent protections and strategic patent litigation—a key factor in patent litigation economics and the pharmaceutical patent landscape.
Judicial Findings
While the case ultimately settled before a definitive court ruling, key issues considered by the court or in subsequent filings centered on:
- The strength of patent claims.
- Whether the patent met prior art challenges.
- The scope and territorial restrictions of settlement agreements.
Comparative Industry Context
| Aspect |
Par-TWi Case |
Industry Norms |
Reference Cases |
| Patent validity challenges |
Frequent in Hatch-Waxman litigations |
High success rate for Declaratory Judgments |
Abbott Labs v. TorPharm, Inc. (1991) |
| Settlement agreements |
Common, often criticized as “pay-for-delay” |
Industry trend toward patent settlements |
FTC v. Actavis, 570 U.S. 136 (2013) |
| Market exclusivity periods |
Long-term exclusivity via patent defense predates patent expiry |
Industry seeks extended exclusivity |
Teva v. Sandoz, 137 S. Ct. 831 (2017) |
Implications for Industry and Stakeholders
- Patent robustness remains critical for innovator companies to defend market share.
- Strategic litigation can result in licensing, settlement, or market delay, influencing pricing and market competition.
- Regulatory and legal trend zones in on settlement practices, with proposals to curb anti-competitive agreements.
Key Takeaways
- The Par v. TWi case exemplifies a typical Hatch-Waxman patent dispute, highlighting the importance of patent strength and strategic litigation.
- Settlements are prevalent and often favorable to patent holders, but they can face regulatory scrutiny under antitrust laws.
- Companies need to balance patent enforcement with potential for litigation challenge and consider alternative strategies such as patent reliance or licensing.
FAQs
1. What federal law underpins patent litigation in drug patent disputes like Par v. TWi?
The Hatch-Waxman Act (21 U.S.C. § 355) underpins pharmaceutical patent disputes by allowing generic companies to challenge patents through Paragraph IV certification, often leading to patent infringement lawsuits.
2. How does a Paragraph IV certification influence litigation?
Paragraph IV certification asserts that the patent is invalid or not infringed, prompting patent holders to sue within 45 days of notification, triggering an automatic 30-month stay on FDA approval, and initiating patent infringement litigation.
3. What are typical settlement terms in pharmaceutical patent litigation?
Settlements often include licensing agreements, patent term extensions, market entry dates, and sometimes “pay-for-delay” arrangements, where the generic agrees to delay entry in exchange for compensation.
4. How does patent validity impact market entry for generics?
Patent validity, if upheld, prevents generics from entering the market until patent expiry or until invalidity is established, directly affecting market share and profitability.
5. What recent legal developments influence pharmaceutical patent litigation?
The Supreme Court’s ruling in FTC v. Actavis (2013) scrutinized pay-for-delay agreements, and amendments to antitrust laws aim to curb anti-competitive patent settlements, influencing litigation strategies.
References
[1] U.S. District Court for the District of New Jersey. Case No. 1:15-cv-00698. (2015).
[2] Hatch-Waxman Act, 35 U.S.C. § 271(e)(2).
[3] FTC v. Actavis, Inc., 570 U.S. 136 (2013).
[4] Teva Pharmaceuticals USA, Inc. v. Sandoz Inc., 137 S. Ct. 831 (2017).
[5] Industry reports on pharmaceutical patent litigation trends, 2015–2022.
[End of Document]
